1
Indications / Contraindications
Primary Indications
- HCC — unresectable, BCLC B (intermediate stage) — largest body of evidence; standard of care per EASL/AASLD guidelines
- Bridge to liver transplantation — prevent dropout while on waitlist; maintain within Milan criteria
- Downstaging for transplant eligibility — Metroticket criteria; coordinate with hepatology and transplant surgery
- Residual HCC after RFA — salvage TACE for incompletely ablated tumors
Secondary / Off-Label
- Hepatic metastases — NET most responsive; mCRC less so; breast, uveal melanoma
- Intrahepatic cholangiocarcinoma (iCCA) — emerging role; typically DEB-TACE; use in unresectable disease
Child-Pugh Patient Selection
- Child-Pugh A — good candidate
- Child-Pugh B7 — carefully selected cases
- Child-Pugh B8–9 — very high risk; extreme caution
- Child-Pugh C — contraindicated; TACE accelerates hepatic failure in decompensated cirrhosis
cTACE — Conventional TACE
- Lipiodol (ethiodized oil) + chemotherapy emulsified and injected into tumor-feeding artery
- Standard chemo: doxorubicin 50 mg, cisplatin 50–100 mg, mitomycin C 10 mg (single agent or combination; per institutional protocol)
- Followed by bland embolic: gelfoam pledgets or 100–300 μm microspheres to achieve stasis
- Lipiodol = chemotherapy carrier + imaging marker; brilliant white on CT = tumor retention
DEB-TACE — Drug-Eluting Bead
- DC Beads or LC Beads loaded with doxorubicin (100–300 μm); deployed directly into tumor feeder
- More predictable chemotherapy elution; possibly less systemic toxicity
- No lipiodol needed; endpoint = near stasis
- Equivalent efficacy to cTACE in randomized trials (PRECISION V, EMERALD)
- Preferred for patients with marginal liver function (lower systemic doxorubicin exposure)
Contraindications
- Decompensated cirrhosis (Child-Pugh C, bilirubin >3, INR >2)
- Hepatic encephalopathy
- Extensive portal vein thrombosis — main PVT = relative to absolute contraindication; segmental/branch PVT = proceed with caution
- Complete biliary obstruction without external drainage (biliary embolization → cholangitis)
- Prior bilio-enteric anastomosis — greatly elevated cholangitis risk; prophylactic antibiotics mandatory if treating
- ECOG performance status >2
- Tumor replacement >50% liver volume
2
Pre-Procedure Checklist
Multidisciplinary tumor board. TACE should ideally be discussed at liver tumor board before proceeding. Oncology, hepatology, and transplant surgery coordination as appropriate.
Cross-sectional imaging (within 4 weeks). CT or MRI liver with contrast. Assess: tumor size, number, vascularity, portal vein and hepatic vein involvement. LI-RADS characterization for HCC. BCLC staging.
Labs. CBC, CMP (bilirubin, LFTs, creatinine), coagulation panel, AFP (tumor marker for HCC). Calculate Child-Pugh score — perform before every treatment session.
Portal vein patency. Doppler US or CT/MRI. Main PVT = high risk for ischemia post-TACE; must reassess risks before proceeding.
Pre-procedure hydration. IV fluids 1–2 L NS before procedure. Renal protection and adequate hydration for contrast load and doxorubicin nephrotoxicity.
Antiemetics + steroids. Ondansetron 4–8 mg IV (doxorubicin causes significant nausea). Dexamethasone 4–8 mg IV to reduce post-embolization syndrome severity.
NPO 6 h minimum. Standard pre-procedure fasting for moderate sedation.
Antibiotic prophylaxis (when indicated). Patients with biliary stents, prior cholangitis, or bilio-enteric anastomosis: piperacillin-tazobactam before TACE. Not routine otherwise.
3
Relevant Anatomy
Hepatic Arterial Supply
- Normal anatomy: Celiac trunk → common hepatic artery → proper hepatic artery → right + left hepatic arteries (bifurcation at porta hepatis)
- Variants in ~25% of patients — replaced right hepatic from SMA most common (~15%); replaced left hepatic from left gastric (~5%). Must catheterize ALL tumor-feeding vessels.
- HCC is hypervascular: ~90–100% hepatic artery supply vs. normal liver (75% portal vein, 25% hepatic artery). This differential vascularity allows selective tumor targeting while sparing normal liver parenchyma.
- Segmental/subsegmental targeting: More selective catheterization = less normal liver injury = better tolerance. Target one or two segments when possible.
Non-Target Embolization Risks
- Right gastric artery — lesser curvature of stomach; gastric ulceration if embolized
- Cystic artery — cholecystitis (radiation cholecystitis with cTACE); coil-protect if in field
- Falciform artery — anterior abdominal wall injury
- Phrenic artery contributions — can supply large or dome HCC lesions; must identify
- Stasis endpoint is critical — gelfoam/particles can reflux past stasis into non-target vessels more easily than coils; catheter position is everything
4
Technique
cTACE & DEB-TACE technique + community cards
cTACE — Conventional TACE
Supplies
0.035" Benson
5Fr SOS2
130 cm 2.4 Fr Progreat
Asahi Meister
5 Fr sheath
Lipiodol (5–20 mL vial)
Doxorubicin 50 mg
Contrast + syringes
Gelfoam pledgets or 100–300 μm microspheres
Heparinized saline
cTACE Steps
1
Celiac + SMA arteriography
Define hepatic arterial anatomy in AP and lateral projections. Document tumor-feeding vessels. Identify vessels requiring protection: right gastric artery, cystic artery, falciform, replaced or accessory hepatic vessels. SMA angiogram to identify replaced right hepatic artery (~15% incidence).
2
Superselective catheterization
Advance microcatheter into tumor-feeding vessel (segmental or subsegmental hepatic artery). Confirm tumor blush on selective arteriogram. Document catheter position. More selective = better tumor coverage and less normal liver injury.
3
Lipiodol-chemotherapy emulsion preparation
Mix lipiodol + doxorubicin 50 mg (dissolved in saline). Emulsify between two syringes connected via stopcock until viscous water-in-oil consistency is achieved. Typical lipiodol volume: 5–20 mL depending on tumor size. Do not inject before emulsion is homogeneous.
4
Infuse lipiodol-chemo emulsion
Slowly inject emulsion under fluoroscopy. Watch emulsion flow selectively into tumor (characteristic fluoroscopic opacification). Critical endpoint: stop injection at stasis (forward flow slows to near zero). Do NOT inject past stasis → non-target embolization to stomach, gallbladder, or biliary tree.
5
Bland embolization
After lipiodol delivery: inject gelfoam slurry or 100–300 μm microspheres to achieve proximal stasis in the feeding artery. This retains chemotherapy within the tumor by eliminating arterial washout. Endpoint: complete stasis of the segmental/subsegmental artery.
6
Post-TACE arteriogram
Confirm tumor devascularization and stasis of flow in treated vessel(s). Document residual tumor blush if present (plan for retreatment). AP arteriogram to confirm no filling of gastric, gallbladder, or other non-target vessels.
7
Check for non-target fill
Before removing catheter: confirm no unintended embolization to right gastric territory, gallbladder, or bowel. If non-target fill detected, document carefully and monitor appropriately post-procedure.
DEB-TACE — Drug-Eluting Bead
DEB-TACE Steps (Abbreviated)
1
Same angiography setup as cTACE
Celiac + SMA angiogram, identify anatomy and tumor feeders, superselect tumor-feeding vessel with microcatheter. No vessel protection coiling needed (no lipiodol to protect non-target vessels differently than DEB beads). Catheter position still critical.
2
Load and infuse DC Beads
DC Beads 100–300 μm loaded with doxorubicin (per institutional protocol). Mix with contrast. Do not mix with saline as this can cause the beads to dissociate. Infuse slowly from microcatheter under fluoroscopy. Endpoint = near stasis in the tumor-feeding vessel. No lipiodol; bead deposition is the therapeutic agent.
3
Post-procedure arteriogram
Confirm devascularization. DEB-TACE does not produce lipiodol staining on fluoroscopy — response assessment entirely by follow-up MRI/CT. Document devascularization and stasis on completion angiogram.
Sign in to view and create community cards
5
Troubleshooting
Problem
Tumor not fully devascularized (residual blush)
Likely cause: Additional feeding vessels not yet catheterized — contralateral hepatic artery, right gastric branch contribution, inferior phrenic artery supply to dome lesions.
Next step: Systematically check for additional feeders. Consider additional superselective passes to remaining contributing vessels. If anatomy is exhausted, plan for retreatment at 4–6 weeks after follow-up MRI confirms residual viable tumor.
Problem
Non-target embolization (gallbladder pain, epigastric pain)
Likely cause: Reflux of embolic material into cystic artery (cholecystitis) or right gastric / gastroduodenal territory (gastric ulceration) during injection past stasis.
Next step: Post-procedure imaging to assess. Radiation cholecystitis (dull RUQ pain, gallbladder wall thickening on CT) is usually self-limited; manage conservatively. Gastric ulceration: PPI, close monitoring, hospitalization for significant cases. Document and avoid repeat embolization to same territory.
Problem
Post-TACE liver failure
Likely cause: Occurs typically 1–4 weeks post in patients with pre-existing compromised hepatic reserve. Child-Pugh B8–9 patients most vulnerable. Bilateral treatment or large volume treatment in a single session.
Next step: Monitor LFTs and bilirubin closely post-procedure. Aggressive supportive care — hydration, nutrition, hepatic encephalopathy management. Hepatology consultation. This is the most feared TACE complication; prevention through proper patient selection (Child-Pugh) is paramount.
Problem
Portal vein thrombosis discovered at angiography
Likely cause: PVT may be present but not fully characterized on pre-procedure imaging. Can be progressive in cirrhotic HCC patients.
Next step: Re-evaluate with Child-Pugh score. Main PVT = withhold TACE or use an extremely selective segmental approach with minimal treatment volume. Branch/segmental PVT = proceed with caution, smaller treatment territory. Consider Y-90 (TheraSphere) as alternative — approved for HCC with portal vein thrombosis.
6
Complications
Common / Expected
- Post-embolization syndrome (70–80%) — fever, nausea, RUQ pain, malaise 1–7 days post; almost universal; self-limited; supportive care
- Radiation cholecystitis (~5%) — when cystic artery in treatment field; usually self-limited; cholecystectomy rarely needed
- Transient LFT elevation — expected; resolves 1–2 weeks post; persistent or worsening = hepatic failure warning sign
Serious / Feared
- Hepatic failure (3–5%) — most feared; occurs in decompensated liver; prevent through Child-Pugh screening; aggressive supportive care
- Non-target embolization — gastric ulcer, biliary ischemia; prevented by stasis endpoint discipline
- Biloma / hepatic abscess (~0.5–1%) — biliary tree necrosis; higher risk with biliary stents or bilio-enteric anastomosis
- Hepatic artery thrombosis — rare; limits future treatment options
- Tumor rupture — very rare; emergent embolization
- Renal impairment — contrast + doxorubicin nephrotoxicity; pre-hydration is protective
- Access site complications — hematoma, pseudoaneurysm; standard arterial post-care
7
Post-Procedure Care
Immediate (Day of Procedure)
- Inpatient observation 4–6 h minimum; 23 h overnight admission standard at most centers
- Antiemetics: ondansetron or prochlorperazine PRN
- Pain management: ketorolac, morphine for post-embolization syndrome
- IV hydration: 2–3 L during and after procedure
- Monitor vitals, RUQ exam, urine output
Short-Term Follow-up
- LFTs at 24 h and at 1 week
- AFP at 4 weeks (should decline with effective treatment; rise = residual/progressive disease)
- Imaging response: MRI or CT with contrast at 4–6 weeks — use mRECIST or LI-RADS Treatment Response (LR-TR)
- Resume anticoagulation per baseline risk at 24–48 h if indicated
Retreatment Planning
- Retreatment typically every 6–8 weeks for HCC (until complete response, transplant, or progression)
- CR/PR on mRECIST → next session at 6–8 weeks
- Stable disease → 4–6 weeks, consider different approach (more selective, different embolic)
- Progressive disease → alternative therapy (Y-90, systemic, ablation, transplant workup)
Transplant Bridging Coordination
- Coordinate with hepatology and transplant surgery — treatment response affects waitlist priority
- MELD exception points for HCC require periodic imaging response documentation
- Goal: maintain tumor within Milan criteria throughout waitlist period
- AFP >1,000 ng/mL despite TACE may affect transplant candidacy (institutional variation)
8
Critical Pearls
❖
Child-Pugh A = safe. B7 = careful selection. B8–9 / C = do NOT treat with TACE. Post-TACE hepatic failure in a decompensated liver is the single most preventable complication. Calculate Child-Pugh before every session, not just the first.
❖
Superselective is key. Subsegmental TACE (one subsegment) gives better tumor coverage and less normal liver injury than lobar TACE. Move as distal as possible with the microcatheter. Superselective = less post-embolization syndrome + better outcomes.
❖
Stasis endpoint: stop injecting when forward flow stalls. Over-injection past stasis forces lipiodol-chemo emulsion or beads retrograde into non-target vessels → gastric ulcers, biliary injury. The most common technical error in TACE. Watch fluoroscopy continuously during injection.
❖
Lipiodol on CT at 24 h is your immediate response marker. The brilliant white lipiodol retention in tumor on non-contrast CT means good chemotherapy delivery. Poor retention = insufficient embolization or hypovascular tumor. Use this information to plan retreatment.
❖
DEB-TACE: similar efficacy, lower systemic toxicity. Better for patients with marginal liver function who cannot tolerate the systemic doxorubicin exposure of cTACE. Does not produce lipiodol CT signal — response assessment is entirely by MRI/CT arterial enhancement.
❖
Post-embolization syndrome is universal — prepare patients. Fever, nausea, RUQ pain for 1–7 days. Admission for 23 h observation is common. Hydrate aggressively (2–3 L during and after). Dexamethasone and antiemetics before the procedure blunt the syndrome.
❖
Antibiotic prophylaxis when indicated. Patients with biliary stents, prior cholangitis, or bilio-enteric anastomosis (Whipple, hepaticojejunostomy) → piperacillin-tazobactam before TACE. Hepatic artery occlusion in the setting of biliary-enteric continuity → ischemic cholangitis → liver abscess. This is a life-threatening complication that is entirely preventable.
9
TACE Response Assessment
Modified RECIST (mRECIST) for HCC
- Complete Response (CR): Disappearance of arterial phase enhancement in all target lesions
- Partial Response (PR): ≥30% decrease in sum of viable (enhancing) diameters
- Progressive Disease (PD): ≥20% increase in sum of viable diameters, or new lesions
- Stable Disease (SD): Neither PR nor PD criteria met
LI-RADS Treatment Response (LR-TR)
- LR-TR Nonviable: No arterial phase enhancement = complete treatment response
- LR-TR Equivocal: Equivocal enhancement — likely treated, possible residual; follow closely
- LR-TR Viable: Definite residual arterial enhancement = incomplete treatment; plan retreatment
| Response Category | AFP Trend | Action |
|---|---|---|
| CR (mRECIST) / LR-TR Nonviable | >50% decline from peak | Continue surveillance; next session at 6–8 weeks or transplant evaluation |
| PR (mRECIST) | Declining | Retreatment at 6–8 weeks; continue TACE series |
| SD | Plateau | Retreatment at 4–6 weeks; consider more selective approach or different embolic agent |
| PD / LR-TR Viable (persistent) | Rising or plateau | Reassess — consider Y-90, ablation, systemic therapy (sorafenib, lenvatinib), or transplant workup if applicable |
Response Assessment Checklist
- MRI or CT with contrast at 4–6 weeks post-TACE (arterial, portal venous, and delayed phases)
- Use arterial phase enhancement as primary response criterion (NOT size alone — size-based RECIST 1.1 underestimates response)
- AFP at 4 weeks: >50% decline = favorable; plateau or rise = residual/progressive disease
- Re-treatment decision should incorporate: imaging response, Child-Pugh score at follow-up, patient performance status, and transplant eligibility status
10
References & Resources
Primary sources · Key data · Related procedures
Key Guidelines
- AASLD HCC Practice Guidance 2023
- BCLC Staging and Treatment Algorithm
- EASL HCC Guidelines 2018
- SIR Standards of Practice for TACE
Primary References
- Llovet JM et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-1739.
- Lo CM et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-1171.
- Lencioni R et al. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.
- Padia SA et al. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: comparison of clinical outcomes with conventional chemoembolization in a single center. J Vasc Interv Radiol. 2013;24(2):174-180.